Global Biotech & Pharma Patent (China) Summit 2025
会议介绍
This year, China promulgated the "Regulations of the State Council on the Handling of Foreign-Related Intellectual Property Disputes", and the State Drug Administration issued the "Implementation Measures for the Protection of Drug Trial Data (Trial, Draft for Comments)",
and new changes have also occurred in the policies on pharmaceutical trade secrets.
At the same time, with the changes in the international situation, more and more pharmaceutical companies are paying more attention to intellectual property rights.
This summit will focus on the changes in pharmaceutical intellectual property rights in China, the United States, Europe, Asia-Pacific and other places.
Agenda Overview:
Day 1 Morning：
Interpretation of biomedical intellectual property laws and policies under the new situation
Patent protection in the biomedical field under the new patent law
The particularity of patent applications in the biological field
Comparison of early dispute resolution systems for biopharmaceutical patents in China and the US
International progress in drug trial data protection and related systems
Day 1 Afternoon：
R&D innovation and patent protection in the fields of biotechnology and medicine
Innovative patent research and development trends in the field of biotechnology
Exploration and development of patent application technologies in the fields of gene editing and genetic engineering technologies
Opportunities and challenges brought by patent cliff
Determination and cultivation of high-value patents
Pharmaceutical enterprise trade secret protection and infringement risk prevention
Day 2 Morning：
Trends in biomedical R&D and patent protection from a global perspective
Global biosimilar patent litigation and marketing review
Extended means of protection for pharmaceutical products – SPC
The impact of the US S.150 bill on the marketing of generic drugs and biosimilar drugs
Practical Strategies for European Medical Invention Patent Application and Patent Validation
Day 2 Afternoon：
The balance and game between patent layout and management of innovative drugs and generic drugs
Patent layout of pharmaceutical companies and industry cross-border overseas strategy
Patent avoidance and challenges in current generic drug research and development
The dilemma and development path of patent protection for indications after drug marketing
Drug new use patent layout strategy and authorization confirmation disputes
Partial inviting Companies & Institutions :
|
CNIPA |
EUIPO |
WIPO |
|
PhIRDA |
Eli Lilly and Company |
Novo Nordisk |
|
Johnson & Johnson |
AbbVie |
Merck Sharp & Dohme |
|
Roche |
AstraZeneca |
Novartis |
|
Pfizer |
Amgen |
Sanofi |
|
GileadSciences |
Bristol-Myers Squibb |
Vertex Pharmaceuticals |
|
Regeneron Pharmaceuticals |
Novo Nordisk |
Chugai Pharmaceutical |
|
GSK |
Merck KGaA |
Sun Pharmaceutical |
|
CVS Health |
Daiichi Sankyō |
LONZA |
|
Takeda Pharmaceutical |
Hengrui Pharmaceuticals |
UCB |
|
Argenx |
Alnylam Pharmaceuticals Inc |
Celltrion |
|
Otsuka Holdings |
Galderma Group |
TEVA |
|
WuXi AppTec |
West Pharmaceutical |
BeiGene |
|
Biogen Inc |
LabCorp |
Bayer |
|
Divis Laboratories |
Sandoz |
ICON |
|
Astellas Pharma |
Moderna |
Baxter |
|
Neurocrine Biosciences |
Cipla Ltd., |
Viatris |
|
Hansoh Pharm |
Dr. Reddy's |
Lupin Limited |
|
Servier |
Incyte, Corp |
Genmab |
|
Eisai |
Luoxin Pharmaceutical Group |
CSPC Pharma |
|
Tide Pharmaceutical |
BRILLIANT PHARMACEUTICAL |
Innovent Biologics |
|
Bio-Thera Solutions |
Salubris Pharmaceuticals |
Haiscom pharmaceutical |
|
Easton Biopharmaceuticals |
Hua Medicine |
Genscript Corporation |
|
TransThera Biosciences |
CHIPSCREEN BIOSCIENCES |
Humanwell Pharmaceutical |
|
Fosun Kite Biotechnology |
Hybio Pharmaceutical |
Allist Pharmaceuticals |
|
Xiangxue Life Sciences |
Humanwell Healthcare |
XuanZhu Pharma |
|
Staidson |
Shineway Pharmaceutical |
Kanghong Pharmaceutical |
|
I-Mab Biopharma |
CRDC |
New Era Pharmaceutical |
|
Ascentage Pharma |
ARSUAMOON |
Jiangxi Jemincare Group |
|
Yangzijiang Pharmaceutical |
LintonPharm Co., Ltd. |
Grand Pharmaceutical |
|
Qilu Pharmaceutical |
Shanghai Pharmaceuticals |
Kelun Pharmaceutical |
|
Buchang Pharmaceuticals |
Livzon Pharmaceutical |
SunshineLake |
|
Huahai Pharmaceutical |
Conba Pharmaceutical |
3SBio Inc. |
|
Jiuzhou Pharmaceutical |
Hisun Pharmaceutical |
Simcere Pharmaceutical |
| 票种名称 | 价格 | 原价 | 票价说明 |
| 早鸟票 | ¥3800 | ¥3800 | 参会，午餐，茶歇，活动资料 |